Boston Scientific of Marlborough generated $2.1 billion in sales and $368 million in earnings in its third quarter, the company announced Wednesday.
Those sales beat the company’s guidance range and represents an 11-percent year-over-year growth while earnings were up 13 percent.
Growth was across all segments and geographical locations, according to Boston Scientific, with the company’s Asia, Middle East and Africa division seeing a 20-percent increase in revenue and the company’s medical and surgery arm growing by 15 percent.
The news comes during a quarter in which the company made significant investments such as the $210 million cash offer to buy Georgia gastrointestinal specialist EndoChoice Holdings, Inc.
In the quarter, Ian Meredith was also named the company’s new executive vice president and global chief medical — to begin in January — and the U.S. Food and Drug Administration approved an implanted defibrillator system from Boston Scientific for use with MRI machines.
